LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Axsome Therapeutics Inc

Închisă

SectorSănătate

139.58 1.99

Rezumat

Modificarea prețului

24h

Curent

Minim

139.33

Maxim

139.84

Indicatori cheie

By Trading Economics

Venit

744K

-47M

Vânzări

21M

171M

EPS

-0.94

Marjă de profit

-27.621

Angajați

816

EBITDA

5.5M

-31M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+27.55% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

226M

6.9B

Deschiderea anterioară

137.59

Închiderea anterioară

139.58

Sentimentul știrilor

By Acuity

17%

83%

17 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Axsome Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 nov. 2025, 17:45 UTC

Câștiguri
Principalele dinamici ale pieței

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov. 2025, 17:31 UTC

Câștiguri
Principalele dinamici ale pieței

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15 nov. 2025, 18:03 UTC

Câștiguri

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15 nov. 2025, 15:43 UTC

Câștiguri

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15 nov. 2025, 12:00 UTC

Câștiguri

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15 nov. 2025, 09:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

15 nov. 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15 nov. 2025, 00:08 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov. 2025, 22:35 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov. 2025, 22:32 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov. 2025, 22:29 UTC

Câștiguri

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov. 2025, 22:00 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov. 2025, 21:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

14 nov. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov. 2025, 20:17 UTC

Achiziții, Fuziuni, Preluări

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov. 2025, 19:29 UTC

Market Talk
Câștiguri

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov. 2025, 18:44 UTC

Market Talk
Câștiguri

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

14 nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov. 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Comparație

Modificare preț

Axsome Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

27.55% sus

Prognoză pe 12 luni

Medie 175.25 USD  27.55%

Maxim 202 USD

Minim 148 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAxsome Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

15

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

107.24 / 112.29Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

17 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat